Methods of treating overactive bladder using trospium
The present application provides methods of treating overactive bladder and methods of training or retraining bladder, prolonging symptom relief, improving the quality of life and/or neuronal remodeling in an individual having overactive bladder, by administering an effective amount of trospium locally to the bladder of the individual for at least about 24 hours.
1. A method of treating idiopathic overactive bladder in an individual that has received a prior oral therapy, comprising
i) a first phase comprising continuously administering an effective amount of trospium to the bladder of the individual for at least about 42 days, and
ii) a maintenance phase comprising continuously administering an effective amount of trospium to the bladder of the individual for at least about 42 days,
wherein the maintenance phase is initiated upon symptom reoccurrence following the first phase.
2. The method of claim 1 , wherein trospium is administered to the bladder of the individual for at least about 84 days during the first phase.
3. The method of claim 1 , wherein the individual did not respond or was refractory to the prior oral therapy.
4. The method of claim 1 , wherein trospium is administered to the bladder using an intravesical device.
5. The method of claim 4 , wherein the intravesical device comprises about 850 mg of trospium.
6. The method of claim 4 , wherein about 10 mg/day of trospium is released from the intravesical device over a 42 day period during the first phase or the maintenance phase.
7. The method of claim 1 , wherein the individual experiences symptom relief for at least about 7 days after trospium administration is completed.
8. The method of claim 7 , wherein the individual experiences symptom relief for at least about 6 weeks after trospium administration is completed.
9. The method of claim 2 , wherein the individual experiences symptom relief for at least about 7 days after trospium administration is completed.
10. The method of claim 9 , wherein the individual experiences symptom relief for at least about 4 weeks after trospium administration is completed.
11. The method of claim 7 , wherein the symptom relief comprises a relief of urgency, frequency, or incontinence.
12. The method of claim 9 , wherein the symptom relief comprises a relief of urgency, frequency, or incontinence.
13. The method of claim 1 , wherein the concentration of trospium in the plasma of the individual is less than 2 ng/ml during administration of trospium.
14. The method of claim 1 , wherein the concentration of trospium in the urine is between about 0.1 and about 100 μg/ml during administration of trospium.
15. The method of claim 14 , wherein the concentration of trospium in the urine is between about 2 and about 8 μg/ml during administration of trospium.
16. The method of claim 1 , wherein the individual has an improved quality of life score upon treatment with trospium.
17. The method of claim 1 , wherein the individual has a reduced urinary bother score upon treatment with trospium.
18. The method of claim 1 , wherein trospium is administered to the bladder of the individual for at least about 84 days during the maintenance phase.
19. The method of claim 1 , wherein the maintenance phase is initiated at least about 1 week after the completion of the first phase.
20. The method of claim 1 , wherein the maintenance phase is initiated about 3 months after the completion of the first phase.